Scientists convert beer yeast into small smart drugs

Large -sized peptides are promising medications because they combine accuracy, stability and safety, providing lower side effects than traditional drugs. However, the traditional methods of discovering and testing these peptides are often complex, difficult to control, slow, and not environmentally friendly.

To overcome these restrictions, the researchers designed the common yeast cells of beer yeast to produce various total peptides individually. Each yeast cell is behaved like a small factory that illuminates when the boat is produced, allowing scientists to quickly identify promising peptides. Using the advanced technologies based on brilliance, the team has examined billions of these accurate factors in just a few hours, which is a much faster and more suitable process than the current methods.

“We have dealt with yeast cells so that each one works as” small treatment “.

Ylenia Mazzocato, the co -leader of the study, highlights the sustainability of their approach: “By exploiting the natural mechanism of the yeast, we produce vital and bickering peptide particles, which makes it safe for health and the environment, which is a” really “” green “pharmacy.

The team also explained how these peptides are closely related to their goals. “Using X -ray photography, we have shown the excellent connection properties of these peptides, which confirms their accuracy and strength,” says Zhanna Romanyuk, who contributed to the structural analysis.

This new method provides significant progress to discover drugs, especially for the difficult goals that traditional drugs cannot easily take. “We are pushing the limits of this technology to create large peptides that can provide advanced treatments directly to certain cells, which are likely to revolutionize treatments. This can greatly benefit the patient’s health and have fundamental scientific and economic effects,” Alessandro Angelini, associate professor and study coordinator.

This work was part of the National Plan for Recovery and Flexibility (PNR), with the support of the European Union European Union initiative, which includes multidisciplinary teams from CA ‘FOSCARI University in Venice, Kyoto Institute of Technology (KIT), Chinese Academy, Experts, EPFL In Lausane, and EPFL E EFL) Biotechnology and Chemistry Vitality and mathematical sciences.

Angelini concluded that part of this technology has already obtained a patent by Ca ‘FOSCARI and was recently obtained by Arzanya Srl. “II hopes Arzanya Srl will provide talented young researchers the opportunity to follow their emotions here in Italy, without necessarily the need to move abroad.”